Faeth Therapeutics (FTH) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, via live webcast for stockholders of record as of April 13, 2026.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two nominees, Bob Holmen and Kristian Humer, to the Board of Directors for terms expiring at the 2029 Annual Meeting.

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.

• Approval of common stock issuance upon conversion of Series B Preferred Stock, potentially resulting in a change of control under Nasdaq rules.

• Amendment to increase authorized common stock from 12,500,000 to 300,000,000 shares.

• Approval of the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.

• Authorization to adjourn or postpone the meeting if necessary to solicit votes or pending Nasdaq listing application approval.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals presented at the annual meeting.